Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

Erin Johansson,1 Mercedes Nuñez,2 Axel Svedbom,1 Tatiana Dilla,2 Susanne Hartz3 1Access, Commercialisation & Communications, ICON plc, Stockholm, Sweden; 2Health Outcomes and Real World Evidence, Eli Lilly, Madrid, Spain; 3Global Patient Outcomes and Real World Evidence Internatio...

Full description

Bibliographic Details
Main Authors: Johansson E, Nuñez M, Svedbom A, Dilla T, Hartz S
Format: Article
Language:English
Published: Dove Medical Press 2018-11-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Pharmacoeconomics
cost-utility
biologics
IL-17A antagonists
Online Access:https://www.dovepress.com/cost-effectiveness-of-ixekizumab-versus-secukinumab-in-the-treatment-o-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/cost-effectiveness-of-ixekizumab-versus-secukinumab-in-the-treatment-o-peer-reviewed-article-CEOR

Similar Items